Voting Rights and Shares Capital of the Company
Nanobiotix has released its latest update on the total number of voting rights and shares as of January 31, 2023. The total number of shares outstanding is 34,875,872, with 36,286,976 theoretical voting rights and 36,264,858 exercisable voting rights. This report aligns with the French Commercial Code requirements for transparency. Nanobiotix's lead product candidate, NBTXR3, aims to enhance treatment outcomes for solid tumors, particularly in head and neck cancers. For further details, visit their website at www.nanobiotix.com.
- Lead product candidate NBTXR3 targets solid tumors, potentially improving treatment outcomes.
- Transparency in reporting voting rights aligns with regulatory compliance.
- None.
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Feb. 14, 2023 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| January 31, 2023 | 34,875,872 | 36,286,976 | 36,264,858 |
According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix’s capital if those figures differ from the information previously disclosed.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
__________________________________
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a Shareholders’ Meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.
Contacts
| Nanobiotix | |
Nanobiotix Communications Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Nanobiotix Investor Relations Kate McNeil SVP, Investor Relations +1 (609) 678-7388 investors@nanobiotix.com |
| Media Relations | |
France – Ulysse Communication Pierre-Louis Germain + 33 (0) 6 64 79 97 51 plgermain@ulysse-communication.com | LifeSci Advisors Ligia Vela-Reid +44 (0) 7413825310 lvela-reid@lifesciadvisors.com |
Attachment
FAQ
What are Nanobiotix's total shares and voting rights as of January 31, 2023?
What is the main focus of Nanobiotix's lead product NBTXR3?
How does Nanobiotix ensure transparency in its operations?
Where can I find more information about Nanobiotix?
